OXFORD, UK - Oxford BioDynamics Plc (AIM: OBD), a biotechnology company, has announced the successful outcomes of a clinical study for its EpiSwitch® Colorectal No-Stool Test (NST), which has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback